Taysha Gene Therapies (TSHA) Misses Q1 EPS by 2c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• MoveSmart Rentals Opens Toronto Branch, Expanding Its Canadian Leasing Operations
• Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update